ABSTRACT
BACKGROUND:
Assessing the neuroendocrine (NE) pattern in castration-resistant prostate cancer (CRPC) may prove useful in selecting potential responders to target therapies such as somatostatin analogues. The aim of this study was to define a panel of markers or examinations appropriate to characterize NE differentiation (NED).
METHODS:
Forty-seven patients with CRPC underwent a systematic diagnostic attempt to characterize the NE phenotype using a plasma blood test for chromogranin A (CgA) and immunohistochemical staining of needle biopsy-obtained specimens (CgA, somatostatin receptor 2 [SSTR2], Ki-67, and androgen receptors). In a subgroup of 26 patients, somatostatin receptor scintigraphy using (111)In-DTPA-d-Phe octreotide (octreotide scintigraphy; Octreoscan, Covidien, Hazelwood, MO) was also performed.
RESULTS:
NED was found in 85.1% of patients (if serum CgA, tissular CgA, and tissular SSTR2 were considered separately: 54%, 67%, and 58%, respectively). Only 15% of the 26-patient subgroup had an abnormal octreotide scintigraphy result. Although p-CgA and t-CgA were associated with more aggressive disease with a worse prognosis, patients with positive tissular SSTR2 staining had longer overall survival (OS).
CONCLUSION:
This systematic approach to explore the NED in a quite homogeneous group of patients with CRPC seems reproducible and appropriate. Further investigations are required to validate this panel and better characterize potential responders to targeted therapy.
Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt
Riferimento:
Clin Genitourin Cancer. 2012 Sep;10(3):164-73.
Autori:
Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L, Botteri E, De Cicco C, Musi G, Brescia A, Mazzoleni F, Tringali V, Detti S, de Cobelli O.
Fonte:
Clin Genitourin Cancer. 2012 Sep;10(3):164-73.
Anno:
2012
Azione:
Valutare il modello neuroendocrino (NE) modello nel carcinoma della prostata resistente alla castrazione (CRPC) può risultare utile nel selezionare potenziali agenti terapeutici mirati, come gli analoghi della somatostatina.
Target:
Analoghi della somatostatina/carcinoma della prostata.
Sostanze: